Induction of tumor cell apoptosis by taurine Schiff base copper complex is associated with the inhibition of proteasomal activity

International Journal of Molecular Medicine

Volumn 22, Issue 5, 2008, Pages 677-682

  Zhang, Xia ^a,b   Bi, Caifeng ^a   Fan, Yuhua ^a   Cui, Qiuzhi ^b   Chen, Di ^b   Xiao, Yan ^a,b   Dou, Q Ping ^b  

^a OCEAN UNIVERSITY OF CHINA   (China)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Cancer; Copper; Proteasome inhibitor; Schiff base; Taurine

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN P27; TAURINE SCHIFF BASE COPPER COMPLEX; UNCLASSIFIED DRUG; ATP DEPENDENT 26S PROTEASE; BAX PROTEIN, HUMAN; COPPER; SCHIFF BASE; TAURINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR CELL; UBIQUITINATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; LEUKEMIA CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY);

ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; COPPER; FEMALE; HUMANS; JURKAT CELLS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASOME ENDOPEPTIDASE COMPLEX; SCHIFF BASES; TAURINE; UBIQUITINATION;

EID: 59149107102     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000072     Document Type: Article

References (32)

1. Vizacaya-Ruiz AD, Rivero-Muller A, Ruiz-Ramirez L, et al: Induction of apoptosis by a novel copper-based anticancer compound, Casiopeina π, in L1210 marine leukaemia and CH1 human ovarian carcinoma cells. Toxicology In Vitro 14: 1-5, 2005.
2. Sun RWY, Ma DL, Wong ELM and Che CM: Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans 10: 4884-4892, 2007.
3. Brem S: Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 6: 436-458, 1999.
4. Brewer GJ: Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med 226: 665-673, 2001.
5. Theophanides T and Anastassopoulou J: Copper and carcinogenesis. Crit Rev Oncol Hematol 42: 57-64, 2002.
6. Zowczak M, Iskra M, Torlinski L and Cofta S: Analysis of serum copper and zinc concentrations in cancer patients. Biol Trace Elem Res 82: 1-8, 2001.
7. Chan A, Wong F and Arumanayagam M: Serum ultrafiltrable copper, total copper and caeruloplasmin concentrations in gynaecological carcinomas. Ann Clin Biochem 30: 545-549, 1993.
8. Hochstrasser M: Ubiquitin proteasome, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7: 215-223, 1995.
9. Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell 79: 13-21, 1994.
10. Goldberg AL: Functions of the proteasome: the lysis at the end of the tunnel. Science 268: 522-523, 1995.
11. Dou QP, Smith DM, Daniel KG and Kazi A: Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy. Prog Cell Cycle Res 5: 441-446, 2003.
12. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W and Huber R: Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268: 533-539, 1995.
13. An B, Goldfarb RH, Siman R and Dou QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5: 1062-1075, 1998.
14. Lopes UG, Erhardt P, Yao R and Cooper GM: p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272: 12893-12896, 1997.
15. Daniel KG, Harbach RH, Guida WC and Dou QP: Copper storage diseases: Menkes, Wilsons, and cancer. Front Biosci 9: 2652-2662, 2004.
16. Daniel KG, Gupta P, Harbach RH, Guida WC and Dou QP: Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 67: 1139-1151, 2004.
17. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR and Dou QP: Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 7: 897-908, 2005.
18. Chen D, Cui QC, Yang HJ and Dou QP: Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition the proteasome activity. Cancer Res 66: 10425-10433, 2006.
19. Chen D, Cui QC, Yang HJ, et al: Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 67: 1-9, 2007.
20. Cozzi PG: Metal-Salen Schiff base complexes in catalysis: practical aspects. Chem Soc Rev 33: 410-421, 2004.
21. Cerchiaro G, Aquilano K, Filomeni G, Rotilio G, Ciriolo MR and Ferreira AM: Isatin-Schiff base copper(II) complexes and their influence on cellular viability. J Inorg Biochem 99: 1433-1440, 2005.
22. Adsule S, Barve V, Chen D, et al: Novel Schiff base copper complexes of quinoline-2 carboxyaldehyde as proteasome inhibitors in human prostate cancer cells. J Med Chem 49: 7242-7246, 2006.
23. Zhong X, Yi J, Sun J, Wei HL, Liu WS and Yu KB: Synthesis and crystal structure of some transition metal complexes with a novel bis-Schiff base ligand and their antitumor activities. Eur J Med Chem 41: 1090-1092, 2006.
24. Sreenivasulu B, Vetrichelvan M, Zhao F, Gao S, and Vittal J: Copper(II) complexes of Schiff-base and reduced Schiff-base ligands: influence of weakly coordinating sulfonate groups on the structure and oxidation of 3,5-DTBC. Eur J Inorg Chem 22: 4635-4645, 2005.
25. Tao J, Zhang Y, Tong ML, et al: A mixed-valence copper coordination polymer generated by hydrothermal metal/ligand redox reactions. Chem Commun 13: 1342-1343, 2002.
26. 2O(H2tssb=Schiff Base derived from salicylaldehyde and taurine, phen=1,10 phenathroline). Anal Sci 22: 247-248, 2006.
27. Fox SB, Gasparini G and Harris AL: Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2: 278-289, 2001.
28. Ryan CJ and Wilding G: Angiogenesis inhibitors. New agents in cancer therapy. Drugs Aging 7: 249-255, 2000.
29. Dou QP and Li B: Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat 2: 215-223, 1999.
30. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
31. Almond JB and Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433-443, 2002.
32. Stockert RJ, Grushoff PS, Morell AG, et al: Transport and intracellular distribution of copper in a human hepatoblastoma cell line, HepG2. Hepatology 6: 60-64, 1986.